Effets des bisphosphonates sur différentes étapes de

Ph. Clézardin

Rev Med Suisse 2000; volume -4. 20568

Résumé

Dans le mécanisme de la métastatisation osseuse, les cellules tumorales adhèrent à la matrice extracellulaire. Les bisphosphonates sont capables de réduire cette adhésion.

Bibliographie

Bibliographie
1 Mundy GR. Mechanisms of bone metastasis. Cancer 1997 ; 80 : 1546-56.
2 Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphona. Cancer 1997 ; 80 : 1557-63.
3 Rodan GA, Fleisch AH. Bisphosphonates : Mechanisms of action. J Clin Invest 1996 ; 97 : 2692-6.
4 Kanis JA, Powels TJ, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996 ; 19 : 663-7.
5 Diel IJ, Solomyaer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998 ; 339 : 357-63.
6 Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinom model system. J Bone Min Res 1994 ; 9 : 221-30.
7 Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995 ; 55 : 3551-7.
8 Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997 ; 57 : 3890-4.
9 Van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996 ; 98 : 698-705.
10 Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone me-tastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997 ; 99 : 2509-17.